• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study backs digital diabetes program from Vida Health

January 30, 2023 By Sean Whooley

A person uses the Vida Health digital diabetes management program on their smartphone.
[Image courtesy of Vida Health]
Vida Health announced that a study of its digital health diabetes management program demonstrated improvements in multiple metrics.

San Francisco-based Vida Health published an article in JMIR Formative Research. Results from 1,128 participants demonstrated dramatic improvements in glycemic control. It also highlighted an important relationship between the improved management of depression and diabetes.

Participants enrolled in Vida’s interactive digital health diabetes management program. The company designed it to enable members to manage both physical and mental health.

For patients with baseline HbA1C of >/= 9, the study showed an average 1.9-point reduction in HbA1C at four months and sustained for one year. For those with baseline HbA1C of >/= 9, participants showed a 1.4-point reduction at four months, also sustained for one year.

Participants who saw improvements in depression acuity registered nearly two times greater improvements in HbA1C. Additionally, 61% of participants saw a downward shift in depression acuity, while 55% saw a downward shift in anxiety acuity.

“We’re thrilled to see the positive, sustained impact that our integrated approach is having on our members,” said Richard Frank, MD, Chief Medical Officer for Vida Health. “It’s no surprise to us that patients who are supported as a whole person see better results than those who are treated in silos. It’s clear that patients with diabetes need integrated behavioral health support along with physical health support and we’re excited to be able to offer that to our patients.”

More about the Vida Health study

The study used a single-arm, retrospective design. Patients enrolled used the app-based intervention with one-on-one remote sessions. These sessions took place with a health coach, registered dietitian nutritionist and/or certified diabetes care and education specialist.

Users received structured lessons and tools related to diabetes management and self-care. Participants provided baseline HbA1C values and follow-up values at least 90 days after starting the program.

Vida said its platform demonstrated proven clinical outcomes across a range of conditions. These include diabetes, depression, hypertension, anxiety, and weight loss.

“Our members’ ability to sustain clinically significant short-term outcomes for 12 months is a testament to the effectiveness of Vida’s care model,” said Gretchen Zimmermann, one of the authors on the paper and head of cardiometabolic care and prescribing for Vida Health. “This model is based on human-led care, culturally responsive nutrition guidance, and integrated behavior change interventions for both physical and mental health, and I am extremely proud of our members and how we are able to facilitate their success.”

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Featured, Patient Monitoring, Technology Tagged With: Vida Health

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS